risperidone has been researched along with Sleep Initiation and Maintenance Disorders in 16 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This 53-wk, Phase-III double-blind study was designed to assess the non-inferiority of PP to risperidone long-acting injectable (RIS-LAI) in schizophrenia treatment." | 9.16 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. ( Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B, 2012) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 9.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 9.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 9.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| " This 53-wk, Phase-III double-blind study was designed to assess the non-inferiority of PP to risperidone long-acting injectable (RIS-LAI) in schizophrenia treatment." | 5.16 | A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. ( Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B, 2012) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 5.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 5.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| " Thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. ( Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ, 2004) |
| "The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening." | 5.08 | Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. ( Daniel, DG; Goldberg, TE; Kleinman, JE; Lubick, LJ; Pickar, D; Weinberger, DR; Williams, TS, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, Y | 1 |
| Taga, M | 1 |
| Takahashi, Y | 1 |
| Yamamoto, Y | 1 |
| Masauji, T | 1 |
| Herrera-Huerta, CA | 1 |
| Hernández-Salas, LP | 1 |
| Magallanes-Cano, EM | 1 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Kane, JM | 1 |
| Correll, CU | 1 |
| Goff, DC | 1 |
| Kirkpatrick, B | 1 |
| Marder, SR | 1 |
| Vester-Blokland, E | 1 |
| Sun, W | 1 |
| Carson, WH | 1 |
| Pikalov, A | 1 |
| Assunção-Talbott, S | 1 |
| Fleischhacker, WW | 1 |
| Gopal, S | 1 |
| Lane, R | 1 |
| Gassmann-Mayer, C | 1 |
| Lim, P | 1 |
| Hough, D | 1 |
| Remmerie, B | 1 |
| Eerdekens, M | 2 |
| Salinas Botrán, A | 1 |
| Urgelés Puértolas, D | 1 |
| Peregrin Abad, E | 1 |
| Baandrup, L | 1 |
| Jennum, P | 1 |
| Lublin, H | 1 |
| Glenthoj, B | 1 |
| Andrade, C | 1 |
| Suresh Kumar, PN | 1 |
| Khazaie, H | 1 |
| Rezaie, L | 1 |
| Darvishi, F | 1 |
| Najafi, F | 1 |
| Avis, K | 1 |
| Lindenmayer, JP | 1 |
| Eerdekens, E | 1 |
| Berry, SA | 1 |
| Eren, I | 1 |
| Ozcankaya, R | 1 |
| Altinyazar, V | 1 |
| Addington, DE | 1 |
| Pantelis, C | 1 |
| Dineen, M | 1 |
| Benattia, I | 1 |
| Romano, SJ | 1 |
| Yamashita, H | 1 |
| Mori, K | 1 |
| Nagao, M | 1 |
| Okamoto, Y | 1 |
| Morinobu, S | 1 |
| Yamawaki, S | 1 |
| Byerly, MJ | 1 |
| Greer, RA | 1 |
| Evans, DL | 1 |
| Daniel, DG | 1 |
| Goldberg, TE | 1 |
| Weinberger, DR | 1 |
| Kleinman, JE | 1 |
| Pickar, D | 1 |
| Lubick, LJ | 1 |
| Williams, TS | 1 |
| Doan, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o[NCT00325689] | Phase 4 | 323 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects W[NCT00210717] | Phase 3 | 748 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres[NCT00034775] | Phase 3 | 141 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Treatment options for residual insomnia in schizophrenia.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
7 trials available for risperidone and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Men | 2009 |
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Buttocks; Delayed-Action Preparations; Double-Bli | 2012 |
Treatment of paradoxical insomnia with atypical antipsychotic drugs. A comparison of olanzapine and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Female; Follow-Up Studi | 2013 |
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diarrhea; Drug Administration Schedule; Dr | 2004 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies | 2004 |
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepin | 2005 |
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.
Topics: Akathisia, Drug-Induced; Ambulatory Care; Clozapine; Cognition Disorders; Cross-Over Studies; Humans | 1996 |
8 other studies available for risperidone and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Risk assessment of accidental falls in patients taking trazodone, quetiapine, or risperidone for insomnia: A single-center, case-control study.
Topics: Accidental Falls; Case-Control Studies; Child; Humans; Quetiapine Fumarate; Risk Assessment; Risperi | 2022 |
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedat | 2020 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
[Postpartum psychosis associated with cabergoline].
Topics: Adult; Antipsychotic Agents; Cabergoline; Cesarean Section; Dopamine Agonists; Ergolines; Female; Ha | 2013 |
Treating residual insomnia in schizophrenia: examining the options.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
Risperidone-induced rabbit syndrome in mood disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Hallucinations; Humans; M | 2004 |
Behavioral stimulation associated with risperidone initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Confusion; Female; Humans; | 1995 |
Risperidone for insomnia in PDDs.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; | 1998 |